Eiger Biopharmaceuticals Inc (EIGR) Gross Profit Margin starting from the fourth quarter 2023 to fourth quarter 2022, Profitability Trends and Ranking, Fundamental Ratios - CSIMarket
CSIMarket Company Name, Ticker, Customers, else..
 


• Gross Margin
• EBITDA Margin
• Operating Margin
• Net Margin
• Pre-Tax Margin
• Effective Tax Rate
• Free Cash Flow Margin
• Cash Flow Margin
Eiger Biopharmaceuticals Inc   (NASDAQ: EIGR)


Eiger Biopharmaceuticals Inc 's Gross Profit Margin by quarter

Trends, Rankings, Statistics


Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

EIGR Gross Profit Margin (Dec 31 2023)
Q4 		(Sep 30 2023)
Q3 		(Jun 30 2023)
Q2 		(Mar 31 2023)
Q1 		(Dec 31 2022)
Q4
Y / Y Revenue Change 41.06 %
Seq. Revenue Change 18.51 %
Revenue In Millions $3.80
Gross Profit Margin 94.5 %
Gross Profit Margin Total Ranking # 230
Gross Profit In Millions $3.59
Y / Y Gross Profit Change 52.87 %
Seq. Gross Profit Change 16.16 %


Commenting fourth quarter 2023 Gross Profit Margin
Eiger Biopharmaceuticals Inc has managed to improve its Revenue sequentially to $3.80 millions by 18.51 % faster than Gross Profit increase of 16.16 % to $3.59 millions, this led to contraction in Gross Profit Margin to 94.5 %, but the Eiger Biopharmaceuticals Inc IV. Quarter Gross Profit Margin remained above company average rate of 91.72%.


Observing fourth quarter 2023 results within Biotechnology & Pharmaceuticals industry 6 other companies have achieved higher Gross Profit Margin. While Gross Profit Margin overall ranking has deteriorated relative to the three months before, from 166 to 230.
Learn about Gross Margin
EIGR's Gross Profit Margin fourth quarter 2023 Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry # 7
Healthcare Sector # 29
Overall # 226

Gross Profit Margin Statistics
High Average Low
98.55 % 91.72 % 69.41 %
(Mar 31 2021)   (Sep 30 2022)


EIGR Gross Income Trends • More of EIGR's Profitabilty Ratios • EIGR Stock Quotes and Charts


Other Gross Profit Margin Profitability Ratios
EIGR's Cumulative Gross Profit Margin
Biotechnology & Pharmaceuticals Industry Gross Profit Margin Trends and Statistics
Healthcare Sector Gross Profit Margin Statistics
Gross Profit Margin Profitability Trends for overall market
EIGR's Gross Profit Margin Profitability versus Biotechnology & Pharmaceuticals Industry, Healthcare Sector and total Market
Highest Ranking Gross Profit Margin
Lowest Ranking Gross Profit Margin
Gross Profit Margin Profit Margin for EIGR's Competitors
Gross Profit Margin Profit Margin for Eiger Biopharmaceuticals Inc 's Suppliers
Gross Profit Margin Profit Margin for EIGR's Customers

You may also want to know
EIGR's Annual Growth Rates EIGR's Profitability Ratios EIGR's Asset Turnover Ratio EIGR's Dividend Growth
EIGR's Roe EIGR's Valuation Ratios EIGR's Financial Strength Ratios EIGR's Gross Profit Growth
EIGR's Roa EIGR's Inventory Turnover Ratio EIGR's Growth Rates EIGR's Dividend Comparisons


Companies with similar Gross Profit Margin in the quarter ending Dec 31 2023, within Biotechnology & Pharmaceuticals Industry Gross Profit MarginDec 31 2023 MRQ Gross ProfitDec 31 2023 MRQ Revenue
Agenus Inc  99.69 %$ 83.542  Millions$ 83.802  Millions
Neurocrine Biosciences Inc   98.35 %$ 506.700  Millions$ 515.200  Millions
Biocryst Pharmaceuticals Inc   98.33 %$ 91.844  Millions$ 93.401  Millions
Exelixis Inc   95.46 %$ 457.899  Millions$ 479.652  Millions
Argenx Se  95.28 %$ 2,377.075  Millions$ 2,494.910  Millions
Vir Biotechnology Inc   95.25 %$ 15.989  Millions$ 16.787  Millions
Eiger Biopharmaceuticals Inc   94.50 %$ 3.594  Millions$ 3.803  Millions
Fennec Pharmaceuticals Inc   92.96 %$ 9.050  Millions$ 9.735  Millions
Springworks Therapeutics Inc   92.25 %$ 5.025  Millions$ 5.447  Millions
Tarsus Pharmaceuticals Inc   90.70 %$ 11.860  Millions$ 13.076  Millions
Lineage Cell Therapeutics Inc   87.74 %$ 1.832  Millions$ 2.088  Millions
Zeo Scientifix Inc   86.22 %$ 0.995  Millions$ 1.154  Millions
Biontech Se  84.29 %$ 3,605.504  Millions$ 4,277.280  Millions
Aim Immunotech Inc   81.54 %$ 0.053  Millions$ 0.065  Millions
Halozyme Therapeutics Inc   77.27 %$ 177.741  Millions$ 230.039  Millions
Vericel Corporation  74.63 %$ 48.507  Millions$ 64.996  Millions
Biogen Inc   74.09 %$ 1,768.000  Millions$ 2,386.300  Millions
Cyclo Therapeutics Inc   72.91 %$ 0.227  Millions$ 0.311  Millions
Gilead Sciences Inc   70.62 %$ 5,024.000  Millions$ 7,114.000  Millions
Moderna Inc   66.95 %$ 1,882.000  Millions$ 2,811.000  Millions
Scilex Holding Company  66.42 %$ 8.941  Millions$ 13.462  Millions
Qiagen N v   64.91 %$ 1,233.688  Millions$ 1,900.688  Millions
Bio techne Corp  64.78 %$ 176.587  Millions$ 272.587  Millions
Amgen Inc   62.03 %$ 5,084.000  Millions$ 8,196.000  Millions
Creative Medical Technology Holdings Inc   60.00 %$ 0.002  Millions$ 0.003  Millions
Xtant Medical Holdings Inc   59.65 %$ 17.138  Millions$ 28.731  Millions
Adaptive Biotechnologies Corporation  57.16 %$ 26.168  Millions$ 45.784  Millions
Regenxbio Inc   49.41 %$ 10.975  Millions$ 22.213  Millions
Enzo Biochem Inc  49.39 %$ 4.224  Millions$ 8.553  Millions
Dyadic International Inc   49.00 %$ 0.336  Millions$ 0.687  Millions




Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.